Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
177.34
-6.44 (-3.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,339,275
Open
181.46
Bid (Size)
176.00 (100)
Ask (Size)
178.80 (100)
Prev. Close
183.78
Today's Range
176.39 - 182.23
52wk Range
110.03 - 202.41
Shares Outstanding
146,800,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
Today 15:10 EDT
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
Via
StockStory
Topics
Government
Stocks
World Trade
Discover which S&P500 stocks are making waves on Thursday.
↗
Today 15:05 EDT
Via
Chartmill
Performance
YTD
-0.3%
-0.3%
1 Month
-5.7%
-5.7%
3 Month
+0.8%
+0.8%
6 Month
+15.0%
+15.0%
1 Year
+34.3%
+34.3%
More News
Read More
Explore the top gainers and losers within the S&P500 index in today's session.
↗
Today 12:35 EDT
Via
Chartmill
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
April 01, 2026
Via
MarketMinute
Gapping S&P500 stocks in Tuesday's session
↗
March 31, 2026
Via
Chartmill
Why Biogen Stock Sank While the Market Soared on Thursday
↗
March 31, 2026
Via
The Motley Fool
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
March 31, 2026
Via
MarketMinute
Top S&P500 movers in Tuesday's session
↗
March 31, 2026
Via
Chartmill
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
March 31, 2026
Via
AB Newswire
Which S&P500 stocks are moving on Tuesday?
↗
March 31, 2026
Via
Chartmill
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
March 31, 2026
Via
Finterra
Topics
Economy
Intellectual Property
What's going on in today's pre-market session: S&P500 movers
↗
March 31, 2026
Via
Chartmill
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026
From
Biogen Inc.
Via
GlobeNewswire
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
March 28, 2026
From
Biogen Inc.
Via
GlobeNewswire
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
March 19, 2026
From
Biogen Inc.
Via
GlobeNewswire
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
↗
March 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
↗
March 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
March 11, 2026
From
Biogen Inc.
Via
GlobeNewswire
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
March 10, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
March 09, 2026
Via
StockStory
Topics
Artificial Intelligence
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
March 05, 2026
From
Biogen Inc.
Via
GlobeNewswire
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
March 04, 2026
From
Biogen Inc.
Via
GlobeNewswire
3 Value Stocks Walking a Fine Line
February 18, 2026
Via
StockStory
Frequently Asked Questions
Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 177.34
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 04/02/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 26.03B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 26B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.